Visible Alpha BioPharma for Private Equity & Venture Capital - Visible Alpha


BIOPHARMA FOR PRIVATE EQUITY & VENTURE CAPITAL



Activate Your Trial


Augment your Capital IQ Pro subscription with Visible Alpha BioPharma, offering in-depth, drug-level consensus data that gives a clear and accurate view into market expectations and the competitive landscape.


Visible Alpha BioPharma Home

6,300+

Drugs


1,000+

Indications


1,200+

MOAs


250+

Contributing Brokers


Why Visible Alpha

The Gold Standard for Granular, Forward-Looking Consensus Estimates

  • Powerful Idea Generation

    You’re looking for a way to streamline deal sourcing and easily uncover attractive investment candidates. With BioPharma, you can filter over 6,300 drugs by forward-looking financials, parent company, clinical trial phase, indication, mechanism of action (MOA), and more, to conduct robust comps analyses and identify the most appealing targets.

  • Accurate Forecasting

    You want to understand where market expectations are for the assumptions behind drug revenues (e.g., patients, pricing, region, or indication) to support your drug forecasting, but manually scraping data from research reports takes significant time and effort. BioPharma provides unique consensus data on drug revenues and their underlying assumptions, sourced directly from full working sell-side models.

  • Robust Market Sizing

    You’re looking for an objective, trusted third-party source to benchmark and verify your market size estimates, but traditional data sources are often highly subjective. BioPharma provides a bottom-up consensus view of market sizing for drug indications, geographies, therapeutic areas, and MOA, driven by the granularity of our consensus data.

  • In-Depth Competitive Intelligence

    Developing an understanding of the competitive landscape by MOA, indication, or therapeutic area is time-consuming. You need a forward-looking view on competitive intelligence and how the market will evolve over time. BioPharma’s screener allows you to evaluate the competitive field across more than 20 parameters – including specific factors such as patent expiration dates – and provides an unmatched consensus view into competitors through 2040.

What Makes Our Consensus Data Better?

  • More granularity, with an average of over 160 consensus line items per company.
  • Higher source count, with over 250 brokers contributing full working analyst models.
  • Longer-term forecasts, with estimates out to 2040 and beyond on many drugs.
  • Consistently up-to-date, with the latest estimates having been updated in the last 24 hours (on average).
  • Gross and risk-adjusted estimates, provided separately for additional context.